Skip to main content

Table 2 mIHC for TAMs and PD-L1 expression on 24 BL samples (validation cohort 2) stained for PD-L1, CD68, CD163 and c-maf; mIHC for cytoxic T cells on 24 BL samples (validation cohort 2) stained for PD1, CD8 and granzyme B

From: Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program

mIHC for PD-1/PD-L1 expression and macrophage polarization
  eBL (n = 12) sBL (n = 8) iBL (n = 4)
TAM M1 (CD68+/CD163-/c-maf−) 20–40% 30–40% 20–30%
M2 (CD68+/CD163+/c-maf+) 60–80% 60–70% 70–80%
PD-L1 TAMs (PD-L1+/CD163+) 65–80% 20–40% 55–75%
BL cells (MYC+/PD-L1+) 10–30% 0–10% 0–10%
Exhausted cytotoxic T cells CD8+/PD1+/granzyme B- 60–80% 20–40% 60–80%